Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929695 | 0.95 | EPAS1 (0.40) | EPAS1USP2CYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL19929712 | 0.93 | EPAS1 (0.42) | EPAS1USP2CYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL11355828 | 0.86 | EPAS1 (0.32) | EPAS1 | |
| SCHEMBL19929745 | 0.84 | EPAS1 (0.36) | EPAS1 | |
| SCHEMBL19934064 | 0.81 | EPAS1 (0.34) | EPAS1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL11360771 | 0.80 | TSHR (0.37) | EPAS1 | |
| SCHEMBL19934241 | 0.77 | EPAS1 (0.37) | EPAS1USP2CYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL19929739 | 0.77 | EPAS1 (0.32) | EPAS1KDM4EALDH1A1HPGD | |
| SCHEMBL11352370 | 0.74 | — | — | |
| SCHEMBL11354075 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | XIAMEN UNIVERSITY (CN) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065908-A1 | CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | SQLE, COASY, MCCC2 | EPAS1 4885/4885USP2 3096/4885CYP3A4 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.